Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (478)	12/26/2000 8:14:17 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

V1, <<It concerns me when we disagree on a stock. I think CELG is cheap at $31 per share. >> I think that stock is at fair price now (MC~$2.5BB). If overall market is weak it may decline further. T Scripts indicate that sales growth rate is slowing, so we will need real 4Q/1Q-01 sales number for true story. Growth beyond MM is slow. IMO, management impotence in executing post-marketing (other cancer indications) T trials are main reason that I am concern about growth. Few comments on milestone: * Data from the Phase II trial of the first SelCID for the treatment of Crohn s disease (1Q:01). I think that this candidate is dead. * Initiation of Phase III trial with Thalomid in MDS (1Q:01). Maybe! * Initiate Phase II/III trial of Thalomid for the treatment of colorectal cancer (1Q:01). What combination? They still do not have clear picture about what may work well. Standard and new therapies for CC are rapidly evolving. * Announcement of Phase I/II data for IMiDs in the treatment of multiple myeloma (2Q:01). I am not convinced yet that IMiDs will be as effective as T? * Announcement of Thalomid Total Therapy data for the treatment of early multiple myeloma (2Q:01). * IND for a SERM for the treatment of cancer (2Q:01). * FDA approval of Attenade (late 2Q:01 or early 3Q:01). Did Novartis submitted NDA? I do not expect quick FDA review, 9 months min. Launch, at best, 1H-02. * Launch of Attenade (3Q:01). * Announcement of a drug development partnership coming out of the Signal pipeline (1H:01). I am interested in Signal’s selective and sub-P38 MAK program. However, didn't hear anything new on this one. Best in New Year to all. Miljenko